ATE482212T1 - Pyrrolotriazinverbindungen - Google Patents

Pyrrolotriazinverbindungen

Info

Publication number
ATE482212T1
ATE482212T1 AT05763768T AT05763768T ATE482212T1 AT E482212 T1 ATE482212 T1 AT E482212T1 AT 05763768 T AT05763768 T AT 05763768T AT 05763768 T AT05763768 T AT 05763768T AT E482212 T1 ATE482212 T1 AT E482212T1
Authority
AT
Austria
Prior art keywords
compounds
useful
growth factor
factor receptors
pyrrolotriazine compounds
Prior art date
Application number
AT05763768T
Other languages
English (en)
Inventor
Ashvinikumar Gavai
Harold Mastalerz
Jean-Paul Daris
Pierre Dextraze
Philippe Lapointe
Edward Ruediger
Dolatrai Vyas
Guifen Zhang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE482212T1 publication Critical patent/ATE482212T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
AT05763768T 2004-07-01 2005-06-22 Pyrrolotriazinverbindungen ATE482212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58476804P 2004-07-01 2004-07-01
PCT/US2005/022059 WO2006007468A1 (en) 2004-07-01 2005-06-22 Pyrrolotriazine compounds

Publications (1)

Publication Number Publication Date
ATE482212T1 true ATE482212T1 (de) 2010-10-15

Family

ID=35784205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763768T ATE482212T1 (de) 2004-07-01 2005-06-22 Pyrrolotriazinverbindungen

Country Status (6)

Country Link
US (1) US7102003B2 (de)
EP (1) EP1773791B1 (de)
AT (1) ATE482212T1 (de)
DE (1) DE602005023732D1 (de)
ES (1) ES2350697T3 (de)
WO (1) WO2006007468A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
TW200600513A (en) * 2004-06-30 2006-01-01 Bristol Myers Squibb Co A method for preparing pyrrolotriazine compounds
US7504521B2 (en) * 2004-08-05 2009-03-17 Bristol-Myers Squibb Co. Methods for the preparation of pyrrolotriazine compounds
TW200618803A (en) 2004-08-12 2006-06-16 Bristol Myers Squibb Co Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
US7894174B2 (en) * 2004-08-23 2011-02-22 Monolithic Power Systems, Inc. Method and apparatus for fault detection scheme for cold cathode fluorescent lamp (CCFL) integrated circuits
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
TW200635927A (en) * 2004-12-22 2006-10-16 Bristol Myers Squibb Co Synthetic process
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8063208B2 (en) 2006-02-16 2011-11-22 Bristol-Myers Squibb Company Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
CN101453818B (zh) 2007-11-29 2014-03-19 杭州茂力半导体技术有限公司 放电灯的电路保护和调节装置
US9732320B2 (en) 2008-01-18 2017-08-15 The Brigham And Women's Hospital, Inc. Selective differentiation, identification, and modulation of human TH17 cells
US20110086850A1 (en) * 2008-04-11 2011-04-14 Board Of Regents, The University Of Texas System Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy
ES2539620T3 (es) 2008-12-19 2015-07-02 Cephalon, Inc. Pirrolotriazina como inhibidor de ALK y de JAK2
US20240132521A1 (en) 2022-08-22 2024-04-25 Iambic Therapeutics, Inc. Compounds and methods for modulating her2
US20250276984A1 (en) * 2024-02-20 2025-09-04 Iambic Therapeutics, Inc. Solid state forms of her2 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2163399A1 (en) 1994-11-24 1996-05-25 Katsuhiro Kawano Triazine derivative, chymase activity inhibitor and nitric oxide production inhibitor
JP3621706B2 (ja) 1996-08-28 2005-02-16 ファイザー・インク 置換された6,5―ヘテロ―二環式誘導体
JP4649046B2 (ja) 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
US6787545B1 (en) * 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
US6670357B2 (en) * 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US6867300B2 (en) * 2000-11-17 2005-03-15 Bristol-Myers Squibb Company Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
GEP20063915B (en) 2000-11-17 2006-09-11 Bristol Myers Squibb Co PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS
TW200300350A (en) * 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
TW200306841A (en) * 2002-04-23 2003-12-01 Bristol Myers Squibb Co Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
PT1497019E (pt) 2002-04-23 2015-09-10 Bristol Myers Squibb Co Compostos de pirrolotriazina anilina úteis como inibidores de quinase
TW200407143A (en) * 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
TW200420565A (en) * 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines

Also Published As

Publication number Publication date
EP1773791B1 (de) 2010-09-22
US20060014745A1 (en) 2006-01-19
EP1773791A1 (de) 2007-04-18
US7102003B2 (en) 2006-09-05
DE602005023732D1 (de) 2010-11-04
ES2350697T3 (es) 2011-01-26
WO2006007468A1 (en) 2006-01-19
EP1773791A4 (de) 2009-08-26

Similar Documents

Publication Publication Date Title
MY145634A (en) Pyrrolotriazine compounds as kinase inhibitors
TW200420565A (en) C-6 modified indazolylpyrrolotriazines
MXPA04004492A (es) Indazolilpirrolotriazinas c-5 modificadas.
MXPA05000715A (es) Inhibidores novedosos de cinasas.
WO2006007378A3 (en) Pyrrolotriazine kinase inhibitors
CY2021019I1 (el) Παραγωγα ν4-φαινυλ-κιναζολινο-4-αμινης και σχετικες ενωσεις ως αναστολεις υποδοχεα κινασης τυροσινης τυπου i erbb για τη θεραπεια υπερπολλαπλασιαστικων ασθενειων
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
WO2005065266A8 (en) Di-substituted pyrrolotriazine compounds
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
ATE540696T1 (de) Erbb2-antagonisten für die tumorschmerztherapie
ATE482212T1 (de) Pyrrolotriazinverbindungen
NO20061320L (no) Kinazolinderivater som antitumor agenter
NO20026196D0 (no) Kinazolinditosylatsalt forbindelser
SG178591A1 (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
ATE557026T1 (de) Vasopressin v1a antagonisten
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
WO2005058245A3 (en) Synthetic process
EA200601176A1 (ru) 3-цианохинолиновые производные с антипролиферативной активностью
UA90659C2 (ru) Аналоги хиназолина как ингибиторы рецепторных тирозинкиназ
TW200635927A (en) Synthetic process
ATE421510T1 (de) Kompetitive atp-kinasehemmer
WO2006135796A3 (en) Crystalline forms of a pyrrolotriazine compound
UA97235C2 (ru) Производные хиназолина и конденсированного пиримидина в качестве ингибитора erbb

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties